TLIS
Income statement / Annual
Last year (2023), Talis Biomedical Corporation's total revenue was $412.00 K,
a decrease of 88.72% from the previous year.
In 2023, Talis Biomedical Corporation's net income was -$62.01 M.
See Talis Biomedical Corporation,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$412.00 K |
$3.65 M |
$0.00 |
$10.94 M |
$3.98 M |
$2.39 M |
| Cost of Revenue |
$41.00 K
|
$8.39 M
|
$2.62 M
|
$1.37 M
|
$0.00
|
$0.00
|
| Gross Profit |
$371.00 K
|
-$4.74 M
|
-$2.62 M
|
$9.56 M
|
$3.98 M
|
$2.39 M
|
| Gross Profit Ratio |
0.9
|
-1.3
|
0
|
0.87
|
1
|
1
|
| Research and Development Expenses |
$40.69 M
|
$70.83 M
|
$157.59 M
|
$89.02 M
|
$23.81 M
|
$18.39 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$13.10 M
|
$6.86 M
|
$5.43 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$28.21 M
|
$40.73 M
|
$42.42 M
|
$13.10 M
|
$6.86 M
|
$5.43 M
|
| Other Expenses |
-$1.72 M
|
-$1.16 M
|
-$2.62 M
|
-$1.37 M
|
-$3.98 M
|
$0.00
|
| Operating Expenses |
$67.19 M
|
$110.40 M
|
$197.39 M
|
$100.75 M
|
$26.70 M
|
$21.43 M
|
| Cost And Expenses |
$67.23 M
|
$118.79 M
|
$200.01 M
|
$102.12 M
|
$26.70 M
|
$21.43 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$54.00 K
|
$42.00 K
|
$93.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$770.00 K
|
$11.60 M
|
$2.62 M
|
$1.37 M
|
$726.00 K
|
$647.00 K
|
| EBITDA |
-$66.05 M |
-$101.41 M |
-$189.42 M |
-$89.76 M |
-$25.97 M |
-$20.78 M |
| EBITDA Ratio |
-160.3
|
-27.77
|
0
|
-8.21
|
-6.53
|
-8.7
|
| Operating Income Ratio |
-162.17
|
-30.86
|
0
|
-8.34
|
-6.71
|
-8.97
|
| Total Other Income/Expenses Net |
$4.81 M
|
-$306.00 K
|
$7.97 M
|
$54.00 K
|
-$775.00 K
|
$93.00 K
|
| Income Before Tax |
-$62.01 M
|
-$113.01 M
|
-$192.04 M
|
-$91.13 M
|
-$27.47 M
|
-$21.34 M
|
| Income Before Tax Ratio |
-150.5
|
-30.95
|
0
|
-8.33
|
-6.91
|
-8.93
|
| Income Tax Expense |
$0.00
|
$0.00
|
-$1.58 M
|
-$54.00 K
|
-$42.00 K
|
$93.00 K
|
| Net Income |
-$62.01 M
|
-$113.01 M
|
-$190.46 M
|
-$91.08 M
|
-$27.43 M
|
-$21.34 M
|
| Net Income Ratio |
-150.5
|
-30.95
|
0
|
-8.33
|
-6.9
|
-8.93
|
| EPS |
-34.12 |
-63.65 |
-126.13 |
-314.06 |
-182.88 |
-141.85 |
| EPS Diluted |
-34.12 |
-63.65 |
-126.13 |
-314.06 |
-182.88 |
-141.85 |
| Weighted Average Shares Out |
$1.82 M
|
$1.78 M
|
$1.51 M
|
$290.00 K
|
$150.00 K
|
$150.42 K
|
| Weighted Average Shares Out Diluted |
$1.82 M
|
$1.78 M
|
$1.51 M
|
$290.00 K
|
$150.00 K
|
$150.42 K
|
| Link |
|
|
|
|
|
|
